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Abstract
Background: Diagnosis of primary immunodeficiencies (PIDs) is complex and cumbersome yet important for the
clinical management of the disease. Exome sequencing may provide a genetic diagnosis in a significant number of
patients in a single genetic test.
Methods: In May 2013, we implemented exome sequencing in routine diagnostics for patients suffering from PIDs.
This study reports the clinical utility and diagnostic yield for a heterogeneous group of 254 consecutively referred
PID patients from 249 families. For the majority of patients, the clinical diagnosis was based on clinical criteria
including rare and/or unusual severe bacterial, viral, or fungal infections, sometimes accompanied by autoimmune
manifestations. Functional immune defects were interpreted in the context of aberrant immune cell populations,
aberrant antibody levels, or combinations of these factors.
Results: For 62 patients (24%), exome sequencing identified pathogenic variants in well-established PID genes. An
exome-wide analysis diagnosed 10 additional patients (4%), providing diagnoses for 72 patients (28%) from 68
families altogether. The genetic diagnosis directly indicated novel treatment options for 25 patients that received a
diagnosis (34%).
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Conclusion: Exome sequencing as a first-tier test for PIDs granted a diagnosis for 28% of patients. Importantly,
molecularly defined diagnoses indicated altered therapeutic options in 34% of cases. In addition, exome
sequencing harbors advantages over gene panels as a truly generic test for all genetic diseases, including in silico
extension of existing gene lists and re-analysis of existing data.
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Background
Primary immunodeficiencies (PIDs) are genetically and
phenotypically heterogeneous disorders characterized by
an inborn increased susceptibility to infections. From
the genetic perspective, over 300 genes have been identi-
fied as monogenic causes of PIDs [1–4]. The majority of
pathogenic variants in PID genes are reported to cause
disease in a purely autosomal recessive (AR) fashion
(69%), compared to an autosomal dominant (AD) (20%),
AR and AD (5%), and X-linked (XL) (6%) manner [1–4].
The phenotype of PID patients ranges from frequent or
more severe relatively common infections to serious clin-
ical manifestations due to rare pathogens that require im-
mediate clinical care to prevent fatality [2]. In addition to
infections, some patients with PIDs can also experience
autoimmune or inflammatory conditions, as well as malig-
nancy and developmental abnormalities [1, 2]. PIDs are
divided in 10 specific subtypes according to the Inter-
national Union of Immunological Societies (IUIS) PID
classification [1]. The clinical variable phenotype of PIDs
makes diagnosing patients based on their respective phe-
notypes challenging. A recent publication describes that
55% of 110 cases were misdiagnosed based on their initial
clinical characteristics [5]. In order to prevent this, a more
robust and rapid identification of the underlying genetic
defect would be of great clinical benefit: a “genotype-first
approach” may provide a molecularly defined diagnosis in
a significant amount of cases.
Genetic diagnosis of PIDs has been available for a rela-
tively long time, but until now it has been complicated
by the need to pinpoint the gene of interest: invariably,
this is linked to the correct (and often difficult) clinical
diagnosis in the first place. Fortunately, the availability
of rapid and cheap sequencing methodologies now al-
lows for more unbiased genetic diagnostics. Exome se-
quencing in particular has been shown to be an effective
tool to elucidate the genetic defect underlying other
types of heterogeneous disorders [6, 7]. We performed
exome sequencing to provide a genetic diagnosis for pa-
tients suffering from a broad range of immune deficits.
The identification of the genetic basis of PIDs provides
insight into the molecular mechanisms of these diseases
and may offer customized treatment options [5, 8–10].
Compared to targeted enrichment approach, exome se-
quencing has several major advantages: first, the in silico
exome gene panel can easily be adjusted upon identifica-
tion of novel PID genes; second, exome-wide analysis al-
lows analysis for variants in novel genes not included in
the gene panel; third, exome sequencing allows genome-
wide data access and hence more reliable detection of
copy number variants (CNVs) and regions of homozy-
gosity (ROH) [5, 11–14]. To reduce the complexity of
the analysis and speed up the process, exome sequencing
can be combined with an in silico analysis of a set of
already known disease genes [15].
Due to large genetic and phenotypic heterogeneity of
PIDs, and the rapidly increasing number of PID genes
identified over the last years [1, 2, 16], we implemented
exome sequencing as a single test in routine diagnostics
for PIDs in 2013 in a large tertiary academic hospital
(Radboud University Medical Center). From then until
October 2016, a group of 254 consecutively referred pa-
tients suffering from PIDs have been tested by exome se-
quencing, and here we report on their genetic diagnostic
outcome.
Methods
Samples
Between May 2013 and October 2016, 254 patient DNA
samples (249 families) from the main referring clinics
for exome sequencing to our diagnostic laboratory (160
from The Netherlands, 8 from Finland, and 81 from
Saudi Arabia) were submitted for whole exome sequen-
cing. The average age at testing was 21 years (range from
1month to 79 years), and the male/female distribution
was 117M/137F (details in Additional file 1: Table S1).
Families were counseled and provided consent for “PID
gene panel only” or “gene panel and exome-wide ana-
lysis” as presented here.
Exome sequencing procedure
Genomic DNA was isolated from whole blood. The ex-
perimental workflow of all exomes was performed at
BGI Europe (Beijing Genome Institute Europe,
Copenhagen, Denmark). Exonic regions were enriched
using the Agilent (Agilent Technologies, CA, USA) Sur-
eSelect V4 (n = 85) or V5 (n = 169) kit and sequenced
using an Illumina Hiseq (Illumina, CA, USA) sequencer
with 101-bp paired end reads to a median coverage of >
75x. Sequenced reads were mapped to the hg19
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reference genome using the mapping algorithm from
BWA [17] (version 0.5.9-r16) and called by the GATK
unified genotyper [18] (version 3.2-2). All variants were
annotated using an in-house pipeline for exome analysis
containing variant and gene-specific information,
amongst which the variant population frequencies from
> 5000 in-house exomes [7].
Exome variant interpretation
For the gene panel analysis, a bioinformatic in silico filter
was applied to select for variants affecting the known > 300
PID genes [19]. This gene panel consisted of 263 estab-
lished (OMIM) PID genes in 2013, expanding to 302 genes
in 2016 (all earlier versions available) [19]. Variants were fil-
tered for coding, non-synonymous variants with population
frequencies below 1% in our in-house database (a database
of > 5000 exomes), and evaluated regarding their possible
pathogenicity. The latter was performed using population
frequencies [20], nucleotide conservation scores (PhyloP),
and in silico pathogenicity predictions (SIFT, Polyphen2,
Mutationtaster) combined with genetic and phenotypic
overlap with earlier described cases to estimate the contri-
bution of the genetic variant to disease [21].
Eighty-one percent of diagnosis-negative patients pro-
vided consent for exome-wide analysis. All variants de-
rived from exome sequencing were prioritized for
coding, non-synonymous variants with population fre-
quencies of ≤ 1% in-house and ≤ 5 homozygous occur-
rences reported in EXAC for autosomal recessive
candidates, and allele counts of ≤ 10× in house or ≤ 20×
in EXAC for autosomal dominant candidates [20]. The
exome-wide analysis focused on variants in recently de-
scribed genes and genes involved in immune pathways,
based on GO terms, mouse knockout model phenotypes,
or the Kyoto Encyclopedia of Genes and Genomes
(KEGG). In addition, we filtered for variants in genes
with known NCBI protein-protein interactions with
known disease genes for similar phenotypes [22].
All identified genetic variants were judged on their pos-
sible pathogenicity based on guidelines of the Association
for Clinical Genetic Science and the American College of
Medical Genetics and Genomics [21, 23]. We only consid-
ered variants disease-causing if we found sufficient pheno-
typic overlap with earlier described cases based on OMIM
[24]. In addition, we only report variants classified as class
5 (pathogenic), class 4 (likely pathogenic) (see Table 1 and
Additional file 2: Table S2), or class 3 (uncertain signifi-
cance) (see Additional file 3: Table S3), because the vari-
ants classified as class 2 (likely benign) or class 1 (benign)
are probably tolerated [21, 23].
Homozygosity calling
Regions of homozygosity (ROH) were called using Rare-
VariantVis [13]. Downstream filtering included filtering
for larger (≥ 5Mb) homozygous regions, in which ≥ 85%
of all variants were called to be homozygous.
CNV calling
Copy number variant (CNV) calling was performed
using CoNIFER to calculate RPKM-based absolute Z-
scores [14, 25]. Rare copy number variants affecting
PID-associated genes were followed up similarly as the
earlier described single nucleotide variants (SNVs), small
insertions, or deletions (indels).
Validation of detected variants and follow-up in families
All reported low-quality variant calls (GATK quality by
depth < 500) were confirmed by standard Sanger se-
quencing. Patients with reported class 3 or class 4 vari-
ants were counseled to perform further analyses on their
respective families. To gain more genetic evidence for
causality of the variants, we have performed co-
segregation analysis to confirm de novo mutations or
carrier status in parents.
Immunophenotyping
For 75% of patients, the immunophenotypes were fur-
ther characterized by determining one or more of the
functional immunological defects. This included quanti-
fication of cellular subtypes and antibodies in whole
blood, and measurement of cytokine production capacity
upon in vitro stimulation assays. The latter experiments
were performed similar to previous reports [26]. In brief,
peripheral blood mononuclear cells (PBMCs) were iso-
lated by density centrifugation and cultured with a
medium or a medium supplemented with immune
response-inducing ligands or heat-killed pathogens.
Cytokine production capacity was measured using an
enzyme-linked immunosorbent assay (ELISA).
Results
Patient cohort
In total, 254 patients from 249 families were referred for
diagnostic exome sequencing. Two hundred nineteen
patients presented with unusual bacterial, viral, or fungal
infections or autoimmune manifestations or combina-
tions of such (Fig. 1a, Additional file 1: Table S1 and
Additional file 4: Table S4). Immunophenotype defects
were observed in 194 patients; of those, 133 patients had
aberrant blood cell counts, 102 patients showed altered
antibody profiles, and 31 patients revealed irregular
cytokine production (Fig. 1b, Additional file 1: Table S1
and Additional file 4: Table S4).
Exome sequencing
Whole exome sequencing resulted in an average cover-
age of 120.7× (Agilent SureSelect V4) and 130.2× (Agi-
lent SureSelect V5), covering 95.3% of the exome at least
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Table 1 Expected disease, molecular diagnosis, and potential treatment options for PID patients with diagnoses
Solved European cases
Patient ID Referred
from
Gender Age Clinical diagnosis/expected
disease
Mutation
inheritance
ACMG
variant
class
Mutation(s) identified Treatment
options
Ref treatment
134.1 Finland Female 4 ADA2 deficiency AR (hom) 5/5 CECR1 p.(R169Q/
R169Q)
Anti-TNF
treatment
[40]
1.1 Netherlands Female 50 APECED AR (hom) 5/5 AIRE p.(R257*/R257*)
217.1 Netherlands Female 23 Chronic granulomatous
disease
AR (hom) 5/5 NCF2 p.(Y293*/Y293*) * Specific
prophylaxis
bacterial and
fungal (IFN-γ
treatment)
consider HSCT
[43, 44]
70.1 Netherlands Female 27 Ciliary diskinesia AR (hom) 4/4 RSPH9 p.(M1T/M1T) Possibility for
lung
transplantation
due to diagnosis
of PCD.
[34]
46.1 Finland Female 15 Chronic mucocutaneous
candidiasis
AD 4 STAT1 p.(Q243E/wt) Ruxolitinib;
consider HSCT;
IgG replacement
therapy
[30–32]
149.1 Netherlands Female 55 Chronic mucocutaneous
candidiasis
AD 5 STAT1 p.(Q271P/wt) Ruxolitinib;
consider HSCT;
IgG replacement
therapy
[30–32]
222.1 Netherlands Male 29 Complement deficiency AR (hom) 5/5 C7 p.(G379R/G379R) * Prophylaxis:
vaccination
against
meningococcus
[46]
103.1 Netherlands Male 48 CVID AD 5 NFKB1 p.(S302fs/wt) IgG replacement
therapy
116.1 Netherlands Male 52 CVID AR (hom) 5/5 CECR1 p.(L503fs/L503fs) Anti-TNF
treatment
[40]
169.1 Netherlands Male 57 CVID, malignancies XL 4 MAGT1 p.(S24*) IgG replacement
therapy Mg
supplement
therapy: Clinical
trial NCT02496676
[49]
227.1 Netherlands Male 57 Familial cold
autoinflammatory
syndrome
AD 5 NLRC4 p.(S445P/wt) Anti-IL-1
treatment
[53]
32.1 Netherlands Female 11 months Hermansky-Pudlak
syndrome
AR (CH) 4/4 AP3B1 p.(K59fs/D613fs)
76.1 Netherlands Female 29 HSV infections AD 5 GATA2 p.(R86fs /wt) HSCT [35]
142.1 Netherlands Female 20 Hyper IgE syndrome AD 5 CFTR p.(W1282*/wt)
162.1 Netherlands Male 9 IgG deficiency AD 5 TNFRSF13B p.(C104R/wt)
213.1 Netherlands Male 3 months Interstitial lung disease AR (hom) 4/4 DHFR p.(G21R/G21R) Folinic acid
treatment
[51]
213.2 Netherlands Female 1 Unknown (affected
sibling 213.1)
AR (hom) 4/4 DHFR p.(G21R/G21R) Folinic acid
treatment
[51]
33.1 Netherlands Male 53 Joint, skin, upper
respiratory tract infections
AD 4 CXCR4 p.(S343fs/wt) Plerixafor; CXCR4
antagonist future
treatment option
[29]
69.1 Netherlands Male 9 Kabuki syndrome AD 5 KMT2D p.(E5425K/wt)
29.1 Netherlands Female 28 PAPA syndrome AD 5 PSTPIP1 p.(E250K/wt) Anti-IL-1
treatment
[28]
220.1 Netherlands Female 16 Recurrent infections, IFN-γ
deficiency
AD 4 CARD11 p.(T43P/wt) Glutamine
supplementation
(IFN-γ treatment)
[50]
AD 4 MEFV p.(M680I/wt) Colchicine anti-IL-
1 treatment
[52]
173.1 Netherlands Female 12 Recurrent urticaria AD 5 NLRP1 p.(L332fs/wt) Anti-IL-1
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Table 1 Expected disease, molecular diagnosis, and potential treatment options for PID patients with diagnoses (Continued)
Solved European cases
Patient ID Referred
from
Gender Age Clinical diagnosis/expected
disease
Mutation
inheritance
ACMG
variant
class
Mutation(s) identified Treatment
options
Ref treatment
treatment
52.1 Netherlands Male 4 Shwachman-Diamond AD 5 TERC n.(37A>G/wt)
159.1 Finland Male 1 X-linked
thrombocytopenia
XL 5 WAS p.(V75M) HSCT [39]
Solved Saudi Arabian cases
202.1 Saudi
Arabia
Female 7 Autoimmune
lymphoproliferative
syndrome
AD 5 CARD11 p.(G123S/wt) Glutamine
supplementation;
IFN-γ treatment
[50]
147.1 Saudi
Arabia
Female 6 Autoimmune
lymphoproliferative
syndrome, anti-HCV
AR (hom) 4/4 CASP8 p.(A155S/A155S)
AD 5 CBL c.(1228-2A>G/wt)
83.1 Saudi
Arabia
Male 2 Bare lymphocyte
syndrome II
AR (hom) 5/5 RFXANK p.(D121V/
D121V)
HSCT [37]
AD 5 INSR p(R145C/wt)
106.1 Saudi
Arabia
Male 5 months Bare lymphocyte
syndrome II
AR (hom) 5/5 RAG1 p.(K186fs/K186fs) HSCT [8]
185.1 Saudi
Arabia
Female 8 months Bare lymphocyte
syndrome II
AR (hom) 5/5 RFX5 p.(V378fs/V378fs) HSCT [37]
148.1 Saudi
Arabia
Male 6 Complement deficiency AR (hom) 5/5 C8A p.(Y210*/Y210*) * Prophylaxis:
vaccination
against
meningococcal
disease
[46]
129.1 Saudi
Arabia
Female 8 months Chronic granulomatous
disease
AR (hom) 5/5 CYBA c.(58+4-7del/
58+4-7del)
* Specific
prophylaxis
bacterial and
fungal (IFN-γ
treatment);
consider HSCT
[43, 44]
161.1 Saudi
Arabia
Male 2 Chronic granulomatous
disease
AR (hom) 5/4 CYBA p.(A117E/A117E) * Specific
prophylaxis
bacterial and
fungal (IFN-γ
treatment);
consider HSCT
[43, 44]
165.1 Saudi
Arabia
Female 8 Chronic granulomatous
disease
AR (hom) 5/5 CEBPE p.(R135*/R135*) Consider anti-
inflammatory
therapy
168.1 Saudi
Arabia
Male 3 Chronic granulomatous
disease
XL 5 CYBB p.(E347fs) * Specific
prophylaxis
bacterial and
fungal (IFN-γ
treatment);
consider HSCT
[43, 44]
156.1 Saudi
Arabia
Female 3 Congenital neutropenia,
myelofibrosis
AR (hom) 4/4 VPS45 p.(L410P/L410P) HSCT [47]
113.1 Saudi
Arabia
Female 13 Dyskeratosis congenita AR (hom) 4/4 WRAP53 p.(R387C/
R387C)
122.1 Saudi
Arabia
Female 19 Gray platelet syndrome AR (hom) 5/5 ITGA2B p.(R1026W/
R1026W)
126.1 Saudi
Arabia
Female 11 Hypogammaglobulinemia AR (hom) 5/5 DNMT3B p.(V836M/
V836M)
Consider HSCT;
IgG replacement
therapy
[41]
127.1 Saudi
Arabia
Female 10 Hypogammaglobulinemia,
bronchiectasis
AR (hom) 5/5 ZBTB24 p.(Q498fs/
Q498fs)
Consider HSCT;
IgG replacement
therapy
[42]
127.2 Saudi
Arabia
Female 12 Hypogammaglobulinemia AR (hom) 5/5 ZBTB24 p.(Q498fs/
Q498fs)
Consider HSCT;
IgG replacement
therapy
[42]
138.1 Saudi
Arabia
Male 1 Hypogammaglobulinemia AR (hom) 5/5 AK2 p.(A182D/A182D) Consider HSCT;
IgG replacement
therapy
[45]
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Table 1 Expected disease, molecular diagnosis, and potential treatment options for PID patients with diagnoses (Continued)
Solved European cases
Patient ID Referred
from
Gender Age Clinical diagnosis/expected
disease
Mutation
inheritance
ACMG
variant
class
Mutation(s) identified Treatment
options
Ref treatment
138.2 Saudi
Arabia
Female 4 Hypogammaglobulinemia AR (hom) 5/5 AK2 p.(A182D/A182D) Consider HSCT;
IgG replacement
therapy
[45]
189.1 Saudi
Arabia
Female 4 Hypogammaglobulinemia AR (hom) 5/5 DNMT3B p.(V836M/
V836M)
Consider HSCT;
IgG replacement
therapy
[41]
189.2 Saudi
Arabia
Male 1 Hypogammaglobulinemia AR (hom) 5/5 DNMT3B p.(V836M/
V836M)
Consider HSCT;
IgG replacement
therapy
[41]
196.1 Saudi
Arabia
Male 7 Hypogammaglobulinemia AR (hom) 5/5 DNMT3B p.(V836M/
V836M)
Consider HSCT;
IgG replacement
therapy
[41]
198.1 Saudi
Arabia
Male 2 Hypogammaglobulinemia AR (hom) 5/5 JAK3 p.(R403H/R403H) HSCT [8]
204.1 Saudi
Arabia
Male 6 months Hypogammaglobulinemia AR (hom) 5/5 DNMT3B p.(V836M/
V836M)
Consider HSCT;
IgG replacement
therapy
[41]
100.1 Saudi
Arabia
Female 8 IgG deficiency AD 5 PIK3R1 c.(1425+1G>T/
wt)
IgG replacement
therapy
[38]
186.1 Saudi
Arabia
Male 6 Microcytic anemia AD 4 HBB p.(Q7V/wt)
236.1 Saudi
Arabia
Male 6 Non-immune hemolytic
anemia
XL 5 G6PD p.(V461G) * Dietary:
Avoidance of fava
beans and
specific drugs
[54]
240.1 Saudi
Arabia
Female 2 months Pancytopenia AR (hom) 5/5 MTHFD1 p.(R173C/
R173C)
Folic acid and
folinic acid
treatment
[51]
94.1 Saudi
Arabia
Female 8 Pancytopenia, hyper- and
hypogammaglobulinemia
AR (CH) 5/3 FANCA p.(L910fs/
C1142Y)
114.1 Saudi
Arabia
Female 8 months SCID AR (hom) 4/4 DCLRE1C p.(P117Q/
P117Q)
Consider HSCT [8]
115.1 Saudi
Arabia
Female 8 months SCID AR (hom) 4/4 ZAP70 p.(S524C/S524C) HSCT [8]
105.1 Saudi
Arabia
Male 5 months SCID, HLH XL 5 IL2RG p.(I273fs) Consider HSCT,
IgG replacement
therapy
[8]
112.1 Saudi
Arabia
Male 8 months SCID, Omenn syndrome AR (hom) 5/5 RAG1 p.(K186fs/K186fs) HSCT [8]
146.1 Saudi
Arabia
Male 11 months SCID, HLH AR (hom) 5/5 JAK3 Ex10 Deletion HSCT [8]
154.1 Saudi
Arabia
Male 3 months SCID, BCGitis AR (hom) 4/4 RAG2 p.(K106E/K106E) HSCT [8]
199.1 Saudi
Arabia
Male 3 SCID, Burkitt’s lymphoma AR (hom) 4/4 LCK p.(R480fs/R480fs) HSCT [8]
84.1 Saudi
Arabia
Male 9 Severe eczema AD 4 SAMHD1 p.(F329fs/wt) Consider anti-IL-5
or anti-IL4R
treatment
61.1 Saudi
Arabia
Female 12 Severe infections,
pancytopenia
AD 4 CTLA4 p.(G146R /wt) Abatacept
(recombinant
CTLA4)
[33]
82.1 Saudi
Arabia
Female 4 Severe infections,
thrombocytopenia
AR (hom) 5/5 LRBA p.(T1587fs/
T1587fs)
Abatacept
(recombinant
CTLA4)
[36]
190.1 Saudi
Arabia
Male 4 Severe lung infections AR (hom) 5/5 AK2 p.(A182D/A182D) Consider HSCT;
IgG replacement
therapy
[45]
145.1 Saudi
Arabia
Female 5 months Severe infections,
hypergammaglobulinemia
AR (hom) 5/5 CFTR c.(579+1G>A/
579+1G>A)
239.1 Saudi
Arabia
Female 4 months Severe infections,
hemolytic anemia
AD 4 ANK1 p.(Q1313*/wt)
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20-fold. For the genes within our gene panel, the average
coverage was 132.6× and 93% of the base pairs of these
genes were covered at least 20 times (details in Add-
itional file 5: Table S5).
Exome variant interpretation
For each exome, a bioinformatic in silico panel of genes
was applied as a first-tier test to select for variants af-
fecting the > 300 known PID genes [19]. This list is regu-
larly updated in silico whenever novel PID genes are
discovered. This yielded on average 1542 genetic vari-
ants in known PID genes per individual. Additional fil-
tering for coding, non-synonymous variants and
population frequency ≤ 1% resulted in 10 to 40 variants
per case, which were evaluated on their possible patho-
genicity (Fig. 2). Pathogenic (class 4 or class 5) variants
were identified in at least one of the known PID genes
for 62 patients (24%). Eighty-one percent of genetic-
diagnosis-negative patients provided consent for exome-
wide analysis. (Re-)analysis for variants in recently pub-
lished PID genes and genes causing defects in immuno-
logical sub-pathways yielded an additional (class 4 or
class 5) genetic diagnosis for 10 patients (5% of all
exome-wide analyzed samples; 4% of the entire co-
hort). The combined result of our two-step analysis
provided a (class 4 or class 5) genetic diagnosis in
28% of our patients (Figs. 1c and 2, see Table 1 and
Additional file 2: Table S2). In total, 84 (33%) of all
254 patients were referred from Saudi Arabia; the
diagnostic yield (57%, 48/84 patients) in this sub-
cohort was significantly (P value 2.4e−11, two-sided
Fisher’s exact test) higher than that in patients of
European descent (14%, 24/170). In four of these pa-
tients, two independent pathogenic variants in differ-
ent genes were identified which both contributed to
the patient phenotypes (see Additional file 2: Table
S2. pt 83.1, 147.1, 153.1, and 222.1).
For an additional 12 patients (5%), exome analysis only
identified novel variants in known genes (class 3) with over-
lapping disease phenotypes (see Additional file 3: Table S3).
Homozygosity calling
We identified in total 1399 large (≥ 5Mb) homozygous re-
gions in 165 of 254 patient exomes. One thousand sixty-
seven of these regions were identified in 81 patients from
Saudi Arabia, 318 regions in 68 Dutch patients, and 14 re-
gions in 6 cases from Finland. Thirty-three (82%) of all
homozygous pathogenic variants in autosomal recessive
genes were present in these homozygous regions. In one
Saudi Arabian patient suffering from severe combined
Table 1 Expected disease, molecular diagnosis, and potential treatment options for PID patients with diagnoses (Continued)
Solved European cases
Patient ID Referred
from
Gender Age Clinical diagnosis/expected
disease
Mutation
inheritance
ACMG
variant
class
Mutation(s) identified Treatment
options
Ref treatment
242.1 Saudi
Arabia
Female 4 Severe infections,
leukocytosis,
hypergammaglobulinemia
AD 5 STAT3 p.(V713M/wt) * Specific
prophylaxis
bacterial and
fungal (IFN-γ
treatment)
[32]
160.1 Saudi
Arabia
Female 2 Shwachman-Diamond,
CD3 deficiency
AR (hom) 4/4 PRF1 p.(R410P/R410P) Possible T cell
gene therapy
(under
development)
[48]
153.1 Saudi
Arabia
Male 15 T cell acute lymphoblastic
leukemia
AR (hom) 5/5 NBN p.(Y197fs/Y197fs)
AD 4 RPL5 p.(G140S/wt)
107.1 Saudi
Arabia
Male 21 Thrombocytopenia XL 5 WAS p.(T48A) HSCT [39]
188.1 Saudi
Arabia
Male 6 months TORCH AR (hom) 4/4‡ RNASEH2B p.(D119G/
D119G)
195.1 Saudi
Arabia
Male 1 months Transaldolase deficiency AR (hom) 5/5 TALDO1 p.(Q265fs/
Q265fs)
193.1 Saudi
Arabia
Male 38 Viral infections,
autoimmune
manifestations,
thrombocytopenia
AR (hom) 5/5 C7 p.(G378R/G378R) * Prophylaxis:
vaccination
against
meningococcus
[46]
Table 1 lists clinical diagnoses and identified pathogenic or likely pathogenic genetic mutations in all 72 patients from Europe and Saudi Arabia. In
addition, the table provides potential therapeutic options resulting from identification of the molecular defect
AD autosomal dominant, APECED autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, AR autosomal recessive, CH compound
heterozygous, CVID common variable immune deficiency, HSCT hematopoietic stem cell transplantation, HLH hemophagocytic lymphohistiocytosis,
hom homozygous, IFN-γ interferon- γ, IL-1 interleukin-1, IgG immunoglobulin G, PCD primary ciliary dyskinesia, SCID severe combined
immunodeficiency, TNF tumor necrosis factor, TORCH toxoplasmosis, other, rubella, cytomegalovirus, and herpes simplex infections, XL X-linked
*Indirect measures or prophylaxis
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immunodeficiency (SCID) (T−, B+, NK−; see Table 1 and
Additional file 2: Table S2, 146.1), homozygosity mapping
revealed three large homozygous regions on chromo-
some 19 spanning in total 32.8 Mb (see Additional file 6:
Table S6 and Additional file 7: Additional material and
references). One of these regions overlapped with the
genetic location of JAK3, pathogenic variants which are
a known cause of SCID [1]. In-depth analysis of JAK3
resulted in identification of a homozygous deletion of
exon 10 (Fig. 3).
Fig. 1 Clinical and immunophenotypic overview of the 254 patients included in the diagnostic PID cohort, including percentages of patients
with genetic diagnoses per subgroup. a For 219 patients, pathogens and/or autoimmunity was identified. b Immunophenotypic defects were
characterized in 194 patients. Quantification of blood cell numbers, antibody levels, and cytokine production aided to determine the genetic
diagnosis for these patients. c The diagnostic yield per cohort based on the country from which the patients were referred. Compared to
European patients, a higher percentage of patients from Saudi Arabia received a genetic diagnosis
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Fig. 2 Schematic flowchart overview of the diagnostic exome procedure. Two hundred fifty-four patients from 249 families were referred for
exome sequencing. Gene panel analysis resulted in a genetic diagnosis for 24% of patients. Eighty-one percent of diagnosis-negative patients
provided consent for exome-wide analysis of their data. This analysis resulted in a genetic diagnosis for 10 additional patients (6% of exome-wide
analyzed patients, 4% of the entire cohort). Data of the remaining 146 patients are re-analyzed for analysis of novel and recently published genes
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Unclear pathogenic effect of known TRAF3 variants
In five phenotypically heterogeneous patients, exome se-
quencing identified potentially causative TRAF3 variants;
four of our patients carried the heterozygous p.R118W
variant which was reported earlier in a patient with herpes
simplex encephalitis [27], and one patient carried a
p.V240I variant in heterozygous state (see Additional file 3:
Table S3. pt 42.1, 76.1, 95.1, 132.1, 209.1).
Altered therapy options after genetic diagnosis
For 30 (30/72 = 42%) patients for whom exome sequen-
cing molecularly confirmed the diagnosis of SCID, im-
munodeficiency, centromere instability, and facial
anomalies (ICF) syndrome, chronic granulomatous dis-
ease, or chronic mucocutaneous candidiasis, bone mar-
row transplantation is a published treatment option. For
additional 25 patients (34%) (Table 1), the genetic diag-
nosis defined targeted therapeutic options based on
available literature [8, 28–52].
Discussion
The clinical and genetic heterogeneity of PIDs makes ex-
ome sequencing a valuable first-tier diagnostic tool for
identification of genetic defects underlying PIDs. We
present routine diagnostic exome sequencing in a
phenotypically heterogeneous group of 254 patients
from 249 families. Exome sequencing identified patho-
genic genetic variants (interpreted as class 4 or 5) in
established disease-causing genes in 72 patients (28%).
In four of these patients, a dual genetic diagnosis was
made based on two independent genetic pathogenic var-
iants similar to a report for two developmental pheno-
types [53].
In addition, for 12 patients (5%), we have identified
genetic variants that could possibly contribute to disease,
as these patients presented with OMIM-associated clin-
ical features. However, there was insufficient genetic and
functional evidence to conclude on the pathogenicity of
these variants, which therefore remained variants of un-
known significance (class 3 variants; see Additional file 3:
Table S3).
The diagnostic yield in our study is in line with other
studies describing targeted or exome-wide analyses for
heterogeneous groups of PID patients [5, 11, 54, 55].
Phenotypic selection for homogeneous patient cohorts
with immunological defects result in increased percent-
ages of diagnoses [56–58]. In addition, the PID-
associated genes selected for the gene panels, and the
stringency of variant prioritization, result in (minor) dif-
ferences amongst these studies.
Fig. 3 For one Saudi Arabian SCID patient (146.1), exome-based homozygosity mapping identified a large homozygous region on chromosome
19. Further analysis of JAK3 revealed a homozygous deletion of exon 10
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We observed a higher percentage of genetic diagnosis
for patients referred from Saudi Arabia (57%) compared
to patients from Europe (14%) (Fig. 1c). This significant
(P value 2.4e−11, two-sided Fisher’s exact test) difference
likely arises from two major reasons. Firstly, the Saudi
Arabian patients are referred at a very young age (aver-
age age of 5.5 years compared to 29.3 years for the Euro-
pean cohort, Fig. 4a), which creates a selection bias
towards more severely affected patients. It generally re-
mains challenging to provide molecular diagnoses for
older patients from heterogeneous backgrounds. Vari-
ants causing late-onset disorders are likely present at
higher frequencies in population databases like Gno-
mAD. In addition, the older patients have a higher risk
to be exposed to environmental factors (specific patho-
gens) during their lifetime, highlighting an extra chal-
lenge for PID diagnostics.
Secondly, increased consanguinity levels in the Saudi
Arabian population create a bias towards homozygously
inherited defects. Since the vast majority of known PID
genes (69%) cause disease in an AR fashion, higher rates
of molecular diagnoses can be expected in patients with
more homozygous regions. We detected homozygous
pathogenic variants in 44/254 patients, of which 36 were
referred from Saudi Arabia. The Saudi Arabian patients
have a significantly (P value < 0.0001, Welch’s t-test)
higher number of genomic homozygous regions
compared to the European patients (Fig. 4b, see Add-
itional file 6: Table S6).
Not all homozygous pathogenic variants described in
this study are SNVs or indels commonly identified by
exome sequencing. Homozygosity mapping on exome
data can also reveal regions in which homozygous copy
number variants (CNVs) may occur. As an example, we
focused on a homozygous region on chromosome 19
and could identify a disease-causing homozygous single
exon deletion (patient 146.1, JAK3 exon 10, Fig. 3) in
one SCID patient. The contribution of CNVs such as
single exon deletions to disease is underestimated in
many genetic analyses for PIDs [5], and more systematic
assessments from WES data allow up to 6% disease-
causing CNVs in heterogeneous disorders [25].
Next to the AR-inherited variants, exome sequencing
provided heterozygously rare and private variants that
affect known PID (-associated) genes. In case a novel gen-
etic variant did not pass the conservative guideline thresh-
olds [21, 23], the variant was not considered pathogenic in
this patient. We acknowledge that these stringent criteria
limited the diagnostic outcome of exome sequencing in
our cohort at this stage, but we feel this is important in
order to prevent misdiagnoses. Systematic trio analysis
and functional characterization of each novel missense
variant are warranted to gain further insight in the disease
mechanism on the individual level [6].
Fig. 4 Differences in percentage diagnostic yield based on age and homozygous regions. a The age distribution of the entire cohort, the
European cohort, the Saudi Arabian cohort, and the cases with a genetic diagnosis. b The number of large (> 5 Mb) homozygous regions per
cohort. The increased number of homozygous regions in the Saudi Arabian cohort influenced diagnostic yield of the overall cohort
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In this study, most pathogenic (class 5) variants were
discovered in AR PID genes. There is a bias towards AR
disease because all known AR PID genes are caused by
genetic loss-of-function (LoF) mutations, and most LoF
mutations are considered pathogenic in the ACMG clas-
sification [21]. In contrast, the majority of AD-inherited
PIDs are the result of gain-of-function (GoF) or
dominant-negative mechanisms and are therefore more
likely the result of missense variants, or truncating vari-
ants affecting the last exon or the last 50 nucleotides of
the penultimate exon of the gene [21, 59]. These variants
are only considered pathogenic (class 5) in case the exact
same genetic variant was described earlier. Generally,
these types of variants are less likely pathogenic since
the altered RNA is not predicted to undergo nonsense-
mediated decay and the altered protein is expressed [60].
Exome sequencing analysis identified more patho-
genic variants in specific subgroups of patients com-
pared to others. Similar to earlier reports, severely
affected patients were more likely to receive a genetic
diagnosis [5]. First, evaluation of clinical characteris-
tics revealed that the patients with a higher burden of
infections caused by multiple pathogens and/or auto-
immune manifestations were significantly (P value
0.0002, two-sided Fisher’s exact test) more likely to
receive a genetic diagnosis (40%; 48/121), compared
to patients with infections restricted to a single
pathogen or autoimmune manifestation (14%; 14/98)
(Fig. 1a). Moreover, patients with defects in important
immune cell populations are expected to have more
clinical manifestations. In line with this, a significantly
(P value 0.0014, two-sided Fisher’s exact test) higher
percentage of patients with aberrant blood cell popu-
lations received a genetic diagnosis (37%; 49/133),
compared to patients with normal blood cell popula-
tions (19%; 23/123) (Fig. 1b).
Unclear pathogenic effect of known TRAF3 variants
The exact same pathogenic variants as previously re-
ported in literature were identified in 40 patients from
our cohort. In 36 (90%) of these patients, the presented
immunophenotypic characteristics were similar to earlier
described cases. However, exome sequencing revealed
the same TRAF3 variant p.(R118W) as described in one
patient with HSV encephalitis in four patients (see Add-
itional file 3: Table S3. 44.1, 76.1, 99.1, and 217.1) within
our cohort [27]. Without careful phenotypic assessment
and genetic evaluation, this may result in a false diagno-
sis. Only one of the patients carrying a (paternally inher-
ited) TRAF3 variant (76.1) suffered from HSV
infections, which could also be caused by a (maternally
inherited) frameshift variant in GATA2 p.(R86fs/wt)
[61]. In addition, this variant is relatively common in the
population [20] (population frequency of 0.3%) and ap-
peared slightly more frequent in this study (1.5%). Due
to the high population frequency and disease heterogen-
eity, we speculate that the TRAF3 variant p.(R118W)
might result in a minor broad immunomodulatory de-
fect, and additional genetic and environmental factors
further determine the clinical presentation. We therefore
concluded that this specific variant was not solely the
cause of disease in these patients but should be rather
considered a risk/susceptibility factor. This may be im-
portant for future diagnostic interpretation of this
variant.
Diagnosis by exome-wide analysis
One hundred fifty-six diagnosis-negative patients pro-
vided additional informed consent for exome-wide ana-
lysis of their data. For 10 of these patients, we identified
disease-causing variants in genes that were described
after the latest gene panel update, or genes known to
affect specific sub-pathways that have been previously
published as a genetic cause of similar phenotypes
(Table 1). This is exemplified by one case (70.1) suffering
from recurrent respiratory tract infections for which ex-
ome sequencing identified a homozygous pathogenic
variant in the first amino acid of the protein RSPH9
p.(M1T/M1T) [50]. The genotype-first approach led to
identification of the pathogenic variant leading to ciliary
dyskinesia in this patient, which retrospectively fits the
clinical diagnosis. Re-analysis of exome data for novel
disease genes, as well as further functional, co-
segregation and overlap analysis will ultimately lead to
additional genetic diagnoses for a subset of these
patients.
Genetic diagnosis-based treatment options
In total, 24 patients were molecularly diagnosed with se-
vere immunological phenotypes like severe combined
immunodeficiency (SCID) or immunodeficiency, centro-
mere instability, and facial anomalies (ICF) syndrome,
for which bone marrow transplantation is the main rem-
edy [8]. This treatment option may have been considered
already based on the clinical presentation alone for some
cases; however, referring clinicians valued the molecular
diagnosis of SCID confirming this treatment options.
In addition, six patients were molecularly diagnosed
with chronic mucocutaneous candidiasis (CMC) or
chronic granulomatous disease (CGD), which can be
treated with ruxolitinib (CMC) or IFN-γ (CGD) [46, 62].
However, HSCT has also been published as a therapeutic
option for these diseases [35, 47].
For an additional 25 patients, the genetic diagnosis
provided novel options for targeted therapeutics based
on recent literature (Table 1) [8, 28–52]. The long-term
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effect of these altered therapeutic strategies is still
unknown.
Conclusions
In conclusion, exome sequencing proves to be a valuable
first-tier test for routine diagnostics in PIDs providing a
genetic diagnosis in 28% of patients. In addition, exome
sequencing harbors advantages over gene panels as a
truly generic test for all genetic diseases, including in
silico extension of existing gene lists and re-analysis of
the existing data whenever new knowledge is available.
Importantly, we observed that identifying the molecu-
lar diagnosis in PID patients confirmed HSCT in 42% of
cases as a possible treatment option and identified thera-
peutic target options for additional 34% of cases. This
high amount of possibly “actionable mutations” is un-
common for genetic disorders due to germline muta-
tions, but highlights the possibilities for PIDs in truly
personalized medicine. Future studies combining sys-
tematic trio analysis of exome, genome, and/or tran-
scriptome data will provide patients with additional
diagnoses and insights in targeted therapeutics.
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